Last checked at 4 May 2016 07:00
4 May 2016
Deltex Medical Group plc
("Deltex Medical", "Deltex" or "the Company")
Enhanced performance TruFlow probe launched in UK
Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring (ODM), today announces the launch of TruFlow, a the new, wider beam, single patient disposable probe in the UK and USA.
The reconfigured probe tip design creates a wider ultrasound beam at the focal point in the aorta. Extensive clinical testing in UK hospitals, has confirmed most doctors find that the new probes are easier to focus and that they maintain focus substantially better, even when the patient's position is changed.
The TruFlow probe has been used in all new evaluations in the USA since November 2015.
Ewan Phillips, Deltex Medical's Chief Executive, commented:
"The new wider beam of the TruFlow probes are a major step-forward for Deltex as making the proven ODM technology even easier to use, reduces perceived barriers to change in clinical practice and further reduces the clinical support needed before new customers become independent users."
For further information, please contact:-
Deltex Medical Group plc | 01243 774 837 investorinfo@deltexmedical.com |
Nigel Keen, Chairman | |
Ewan Phillips, Chief Executive | |
Jonathan Shaw, Group Finance Director Barry Curtis, Company Secretary | |
Nominated Adviser & Broker | |
Arden Partners plc | 020 7614 5900 |
Chris Hardie | |
Joint Broker Zeus Capital Limited Phil Walker Dominic Wilson
|
020 3829 5000
|
Financial Public Relations | |
IFC Advisory | 0203 053 8671 |
Tim Metcalfe Graham Herring Heather Armstrong |
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.
Company goal
ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.
The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.
There are over 3,200 monitors installed in hospitals around the world and over 650,000 patients have been treated to date using Deltex Medical's single patient disposable probes.